跳至主要内容
临床试验/NCT04616859
NCT04616859Unknown不适用

Combination of Alcohol and Energy Drinks in a Binge Drinking Pattern: Acute Effects and Gender Differences

Fundació Institut Germans Trias i Pujol2 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2020年10月8日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
32
试验地点
2
主要终点
Change in subjective effects measured with Biphasic alcohol effects scale (BAES)

研究概览

简要总结

The purpose of the study is to assess the relevance of gender in the acute effects (subjective, physiological and driving-related skills) observed after controlled administration of alcohol in a binge-drinking pattern mixed with energy drinks (AmED)

详细描述

Consumption of alcohol mixed with energy drinks (AmED) has increased mainly among young people. Energy drinks (ED) are usually combined with alcohol with the intention of counteracting its effects. However, most studies have not shown a reduction in drunkenness and consumption is related with engagement of risk-taking behaviours like driving under alcohol effects. It is already known that alcohol concentrations and effects are higher in women than in men even after adjusting dose by weight.

The relevance of gender in the acute effects of alcohol associated with ED consumed in a binge-drinking pattern has been poorly studied. A randomized clinical trial will be conducted in healthy volunteers (1:1) and four treatment conditions will be administered: alcohol+ED, alcohol+placebo of ED, placebo of alcohol+ED and placebo of alcohol+placebo of ED. Subjective and physiological effects, driving related skills, and alcohol and caffeine concentrations will be measured along an 8-hours period. A pilot study has been conducted with the first 6 volunteers to select the alcohol doses. In the definitive study 70 g of alcohol in men and 55 g in women will be used.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Double (Participant, Investigator)

盲法说明

Double-blind

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Males and females between 18-40 years old, weight between 50 and 100 kg and BMI (BMI=weight/height²) between 20-28 kg/m². Lower or higher BMIs will be allowed, if the researchers considered that do not suppose a risk to the subjects and do not interfere with the objectives of the study.
  • Recreational alcohol consumption in form of occasional binge-drinking (≥1 episode / month) and at least consumption of 1 unit (10 g, "standard" drink - one alcoholic drink equivalent) per day or its equivalent over the whole week [7 units, 70 g)]) and having experienced drunkenness several times
  • Regular consumption of beverages containing methylxanthines at least 7 per week (coffee, tea, chocolate, cola soda, energy drinks). Consumption of energy drinks at least once.
  • Understand and accept the study's procedures and sign an informed consent form.
  • No evidence of somatic or psychiatric disorders as per past medical history and physical examination.
  • The ECG and general blood and urine laboratory tests performed before the study should be within normal ranges. Minor or occasional changes from normal ranges are accepted if, in the investigator's opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. These changes and their non-relevance will be justified in writing specifically.

排除标准

  • Not fill the inclusion criteria.
  • Pathological history or evidence of a preexisting condition (including gastrointestinal, liver, or kidney disorders) that may alter the absorption, distribution, metabolism or excretion of drugs or symptoms suggestive of drug-induced gastrointestinal irritation.
  • Present history of a substance use disorder according to Diagnostic and Statistical Manual for Mental Disorders (DSM-V), except for nicotine. Past history of mild substance use disorder (corresponding to substance abuse according to DSM-IV) could be included.
  • Previous or actual psychiatric disorders, alcoholism, abuse of prescription drugs or illegal substances or regular consumption of psychoactive drugs.
  • Having donated blood or having participated in this same study in the preceding 8 weeks, or having participated in any clinical trial with drugs in the preceding 12 weeks
  • Having had any somatic disease or having undergone major surgery in the 3 months prior to inclusion in the trial.
  • Individuals intolerant or having experienced a severe adverse reaction to alcohol or energy drinks. Asian subjects with no intolerance or no serious adverse reactions to alcohol could be included.
  • Having regularly taken medication in the month before the trial, except for vitamins, herb-based remedies, dietary supplements that if, according to the Principal Investigator or his appointed collaborators' opinion, they pose no threat to the subjects and they won't interfere with the study's objectives. Single doses of symptomatic drugs taken during the week before the experimental session will not constitute an exclusion criterion if it can be assumed that it has been completely eliminated on the day of the experimental session.
  • Smokers of >5 cigarettes/day
  • Consumption of >20 g/day of alcohol (females) or of >40 g/day (males)
  • Daily consumption of more than 5 coffees, teas, cola drinks or other stimulant or xanthine-containing beverages in the 3 months prior to inclusion in the study.
  • Subjects unable to understand the nature, consequences of the study and the procedures requested to be followed.
  • Subjects with positive serology to Hepatitis B, C or HIV.
  • Pregnant, breastfeeding women and those using hormonal contraception,. Those not using an effective contraceptive (i.e. abstinence, intrauterine devices, barrier methods or partner vasectomy).
  • Women with amenorrhea or suffering severe premenstrual syndrome.

结局指标

主要结局

Change in subjective effects measured with Biphasic alcohol effects scale (BAES)

时间窗: From baseline to 8 hours after administration

Subjective effects of alcohol will be measured using Biphasic alcohol effects scale (0-70 points). Higher scores mean worse outcome. Obtained baseline and 1, 1.30, 2, 3, 4, 6 and 8-h after administration.

Change in psychomotor vigilance task (PVT)

时间窗: From baseline to 6 hours after administration

Test will be performed using a specific software. Mean latency will be measured. Obtained baseline and 1.30, 4 and 6-h after administration.

次要结局

  • Time to reach maximum concentration (tmax) of caffeine in plasma(From baseline to 8 hours after administration)
  • Area under the concentration-time curve (AUC 0-8h) of ethanol blood concentrations(From baseline to 8 hours after administration)
  • Maximum concentration (Cmax) of ethanol in blood(From baseline to 8 hours after administration)
  • Area under the concentration-time curve (AUC 0-8h) of caffeine blood concentrations(From baseline to 8 hours after administration)
  • Maximum concentration (Cmax) of caffeine in plasma(From baseline to 8 hours after administration)
  • Time to reach maximum concentration (tmax) of ethanol in blood(From baseline to 8 hours after administration)
  • Area under the concentration-time curve (AUC 0-8h) of taurine plasma concentrations(From baseline to 8 hours after administration)
  • Time to reach maximum concentration (tmax) of taurine plasma concentrations(From baseline to 8 hours after administration)
  • Change in drunkenness feeling(From baseline to 8 hours after administration)
  • Change in drowsiness feeling(From baseline to 8 hours after administration)
  • Change in palpitations reported by the participant(From baseline to 8 hours after administration)
  • Change in blood pressure(From baseline to 8 hours after administration)
  • Change in heart rate(From baseline to 8 hours after administration)
  • Change in oral temperature(From baseline to 8 hours after administration)
  • Area under the concentration-time curve (AUC 0-8h) of ethanol breath concentrations(From baseline to 8 hours after administration)
  • Maximum concentration (Cmax) of taurine plasma concentrations(From baseline to 8 hours after administration)
  • Change in subjective effects measured with Addiction Research Center Inventory (ARCI)(From baseline to 8 hours after administration)
  • Change in Maddox Wing score (MW)(From baseline to 6 hours after administration)
  • Time to reach maximum concentration (tmax) of ethanol in breath air(From baseline to 8 hours after administration)
  • Change in dizziness feeling(From baseline to 8 hours after administration)
  • Desire to keep drinking(At 1.30 hours)
  • Change in tracking test performance(From baseline to 6 hours after administration)
  • Change in anxiety feeling(From baseline to 8 hours after administration)
  • Change in headache(From baseline to 8 hours after administration)
  • Change in ability and predisposition to drive in certain situations(From baseline to 8 hours after administration)
  • Beverage identification(8 hours after administration)

研究者

发起方
Fundació Institut Germans Trias i Pujol
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验